← FDA DRUG APPROVALS

FDA NDA · NDA020839

PLAVIX

clopidogrel

Sponsor: SANOFI AVENTIS US

APPLICATION
NDA020839
TYPE
NDA
ORIGINAL APPROVAL
1997-11-17
LATEST ACTION
2023-09-12
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

PLAVIX · ReferencePrescription
CLOPIDOGREL BISULFATE EQ 300MG BASE · TABLET · ORAL
PLAVIX · ReferencePrescription
CLOPIDOGREL BISULFATE EQ 75MG BASE · TABLET · ORAL

Approval history

2023-09-12Labeling · Supplement 75 · standardLetterAP
2022-09-16Labeling · Supplement 78 · standardLetterAP
2021-03-01Labeling · Supplement 74 · standardLabelAP
2019-05-17Labeling · Supplement 72 · standardLetterAP
2018-10-11Labeling · Supplement 69 · standardLabelAP
2018-05-25Labeling · Supplement 70 · standardLetterAP
2017-10-31Labeling · Supplement 68 · standardLabelAP
2017-07-10Labeling · Supplement 67 · standardLabelAP
2016-09-16Labeling · Supplement 64 · standardLabelAP
2016-09-16Labeling · Supplement 62 · standardLabelAP
2016-03-24Manufacturing (CMC) · Supplement 63 · priorityAP
2015-07-16Labeling · Supplement 61 · standardLetterAP
2014-05-14Manufacturing (CMC) · Supplement 60 · priorityAP
2014-03-12Manufacturing (CMC) · Supplement 59 · priorityAP
2013-12-12Labeling · Supplement 58 · standardLabelAP
2013-09-12Labeling · Supplement 57 · standardLabelAP
2013-05-24Manufacturing (CMC) · Supplement 56 · priorityAP
2011-12-20Labeling · Supplement 55 · unknownLabelAP
2011-05-06Efficacy · Supplement 51 · priorityLetterAP
2011-05-03REMS · Supplement 53LetterAP
2011-02-01REMS · Supplement 52LetterAP
2010-08-24Labeling · Supplement 48 · standardLetterAP
2010-03-12Labeling · Supplement 42 · standardReviewAP
2009-11-12Labeling · Supplement 44 · unknownLetterAP
2009-05-05Labeling · Supplement 40 · 901 requiredLetterAP
2007-10-22Manufacturing (CMC) · Supplement 39AP
2007-09-20Manufacturing (CMC) · Supplement 38ReviewAP
2007-05-01Labeling · Supplement 37 · standardLetterAP
2006-08-17Efficacy · Supplement 34 · priorityReviewAP
2006-08-04Labeling · Supplement 35 · standardLabelAP
2005-10-14Labeling · Supplement 33 · standardLetterAP
2005-04-26Labeling · Supplement 28 · standardLetterAP
2005-04-25Labeling · Supplement 30 · standardLabelAP
2005-04-25Labeling · Supplement 31 · standardLabelAP
2004-10-13Labeling · Supplement 23 · standardLetterAP
2003-09-29Labeling · Supplement 21 · standardLetterAP
2003-09-29Labeling · Supplement 24 · standardLetterAP
2002-09-10Manufacturing (CMC) · Supplement 20 · priorityReviewAP
2002-06-10Manufacturing (CMC) · Supplement 22 · priorityAP
2002-02-27Efficacy · Supplement 19 · priorityReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →